Published in Oncotarget on March 30, 2014
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J Exp Clin Cancer Res (2014) 1.12
HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer (2014) 1.02
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget (2014) 0.93
The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol (2014) 0.89
Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. Oncotarget (2014) 0.86
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. Bioorg Med Chem (2015) 0.85
RASopathies: unraveling mechanisms with animal models. Dis Model Mech (2015) 0.84
Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting. Blood Cancer J (2015) 0.83
CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget (2016) 0.79
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget (2016) 0.79
Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med (2015) 0.79
Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Radiat Oncol (2015) 0.77
Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. PLoS One (2016) 0.75
Comprehensive pharmacological profiling of neurofibromatosis cell lines. Am J Cancer Res (2017) 0.75
The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo. Oncotarget (2017) 0.75
Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. J Histochem Cytochem (2017) 0.75
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer (1990) 2.74
Targeting the mTOR signaling network in cancer. Trends Mol Med (2007) 2.66
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol (2009) 2.32
Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol (2005) 2.26
The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev (2003) 2.10
TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08
Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med (1991) 1.99
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol (2005) 1.79
Cotargeting survival signaling pathways in cancer. J Clin Invest (2008) 1.68
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63
How does the Schwann cell lineage form tumors in NF1? Glia (2008) 1.63
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell (2005) 1.53
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem (2007) 1.39
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep (2009) 1.32
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med (2009) 1.28
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res (2005) 1.24
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis (2004) 1.15
Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol (1993) 1.13
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov (2013) 1.10
Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep (2012) 1.09
Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol (1998) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol (2008) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget (2011) 1.01
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther (2013) 0.95
PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res (2012) 0.94
FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies. Oncotarget (2013) 0.92
Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST. Sarcoma (2012) 0.90
Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brain Res Bull (2011) 0.88
Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A (2010) 0.84
Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis. Oncotarget (2013) 0.82
Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview. J Child Neurol (2002) 0.77
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature (2005) 6.40
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 5.48
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology (2006) 3.68
Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol (2006) 3.51
Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2012) 3.45
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther (2003) 3.34
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol (2007) 3.24
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet (2006) 2.99
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J (2002) 2.70
Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet (2010) 2.47
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol (2003) 2.31
Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res (2012) 2.29
A transposon and transposase system for human application. Mol Ther (2010) 2.28
Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol (2007) 2.18
Mammalian germ-line transgenesis by transposition. Proc Natl Acad Sci U S A (2002) 2.13
Characterization of Sleeping Beauty transposition and its application to genetic screening in mice. Mol Cell Biol (2003) 2.13
Transposon-tagged mutagenesis in the rat. Nat Methods (2007) 2.06
Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol (2010) 2.00
Transposon mutagenesis of the mouse germline. Genetics (2003) 2.00
RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther (2005) 1.98
Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol (2010) 1.92
Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol (2004) 1.87
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.86
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res (2009) 1.86
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol (2010) 1.85
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest (2003) 1.85
Gene mutations and genomic rearrangements in the mouse as a result of transposon mobilization from chromosomal concatemers. PLoS Genet (2006) 1.84
Target-site preferences of Sleeping Beauty transposons. J Mol Biol (2004) 1.83
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol (2011) 1.82
Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol (2011) 1.82
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80
Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol (2010) 1.74
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology (2007) 1.71
An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology (2011) 1.67
How does the Schwann cell lineage form tumors in NF1? Glia (2008) 1.63
Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J Allergy Clin Immunol (2010) 1.63
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst (2004) 1.62
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet (2005) 1.60
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell (2005) 1.53
Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology (2013) 1.51
Cerebral metastasis and other central nervous system complications of pleuropulmonary blastoma. Pediatr Blood Cancer (2007) 1.50
Pediatric hepatic angiosarcoma: case report and review of the literature. Pediatr Dev Pathol (2004) 1.49
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res (2006) 1.48
Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2009) 1.44
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol (2006) 1.44
Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res (2006) 1.43
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med (2009) 1.41
Issues concerning the treatment of a child with a craniopharyngioma. Med Pediatr Oncol (2002) 1.40
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 1.40
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Overexpression of the epidermal growth factor receptor confers migratory properties to nonmigratory postnatal neural progenitors. J Neurosci (2005) 1.39
High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol (2013) 1.35
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res (2009) 1.34
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther (2003) 1.31
Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res (2005) 1.29
Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer (2008) 1.28
Hopping around the tumor genome: transposons for cancer gene discovery. Cancer Res (2005) 1.28
Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2007) 1.26
Sleeping beauty transposase has an affinity for heterochromatin conformation. Mol Cell Biol (2006) 1.23
Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res (2009) 1.22
Mechanisms and roles of axon-Schwann cell interactions. J Neurosci (2004) 1.21
Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol (2011) 1.20
Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn (2007) 1.19
Insertional mutagenesis in mice: new perspectives and tools. Nat Rev Genet (2005) 1.18
Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry. J Pediatr (2002) 1.17
Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci (2006) 1.17
Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med (2010) 1.16
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther (2007) 1.15
Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell (2008) 1.15
Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet (2013) 1.15